[
  {
    "EudraCT Number:": "2020-001331-26",
    "Sponsor Protocol Number:": "PROLIFIC2020",
    "Sponsor Name:": "Cambridge University Hospitals NHS Foundation Trust",
    "Full Title:": "ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial)",
    "Start Date:": "2020-04-14",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001331-26"
  },
  {
    "EudraCT Number:": "2020-001402-38",
    "Sponsor Protocol Number:": "CTU/2020/352",
    "Sponsor Name:": "University College London",
    "Full Title:": "An international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers.",
    "Start Date:": "2020-10-20",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001402-38"
  },
  {
    "EudraCT Number:": "2020-001889-10",
    "Sponsor Protocol Number:": "STOIC",
    "Sponsor Name:": "University of Oxford, Clinical Trials and Research Governance",
    "Full Title:": "Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation",
    "Start Date:": "2020-06-02",
    "Medical condition:": "COVID 19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001889-10",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001740-26",
    "Sponsor Protocol Number:": "ATOMIC2",
    "Sponsor Name:": "University of Oxford, Clinical Trials and Research Governance",
    "Full Title:": "A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2)",
    "Start Date:": "2020-05-05",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001740-26",
    "Disease 2:": "Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10070255, Term: Coronavirus test positive, Level: PT"
  },
  {
    "EudraCT Number:": "2020-001777-71",
    "Sponsor Protocol Number:": "RAVEN",
    "Sponsor Name:": "Guy\u2019s and St Thomas' NHS Foundation Trust",
    "Full Title:": "Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN",
    "Start Date:": "2020-05-06",
    "Medical condition:": "Severe COVID-19 infection with risk of need for mechanical ventilation.",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001777-71",
    "Disease 2:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT"
  },
  {
    "EudraCT Number:": "2020-002110-41",
    "Sponsor Protocol Number:": "CRUKD/20/002",
    "Sponsor Name:": "Cancer Research UK",
    "Full Title:": "SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb...",
    "Start Date:": "2020-06-18",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002110-41"
  },
  {
    "EudraCT Number:": "2020-001597-30",
    "Sponsor Protocol Number:": "MRx-4DP0004-II-001",
    "Sponsor Name:": "4D pharma plc",
    "Full Title:": "A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)",
    "Start Date:": "2020-05-29",
    "Medical condition:": "Symptoms of Covid-19 infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001597-30"
  },
  {
    "EudraCT Number:": "2020-001750-22",
    "Sponsor Protocol Number:": "20HH5926",
    "Sponsor Name:": "Joint Research Compliance Office",
    "Full Title:": "MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia",
    "Start Date:": "2020-07-09",
    "Medical condition:": "COVID-19 pneumonia",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001750-22",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001448-24",
    "Sponsor Protocol Number:": "RG_20-029COVID-19",
    "Sponsor Name:": "University of Birmingham",
    "Full Title:": "Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 ",
    "Start Date:": "2020-04-15",
    "Medical condition:": "Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19",
    "Disease 1:": "Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035664, Term: Pneumonia, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24",
    "Disease 2:": "Version: 21.1, SOC Term: 100000004855, Classification Code: 10003083, Term: ARDS, Level: LLT"
  },
  {
    "EudraCT Number:": "2020-001721-31",
    "Sponsor Protocol Number:": "SPON-AK-0420",
    "Sponsor Name:": "Hampshire Hospitals NHS TRust",
    "Full Title:": "Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals?",
    "Start Date:": "2020-05-01",
    "Medical condition:": "Covid-19",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001721-31"
  },
  {
    "EudraCT Number:": "2020-003628-18",
    "Sponsor Protocol Number:": "000000",
    "Sponsor Name:": "University of Oxford, Clinical Trials and Research Governance",
    "Full Title:": "Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial",
    "Start Date:": "2020-09-29",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003628-18",
    "Disease 2:": "Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10070255, Term: Coronavirus test positive, Level: PT"
  },
  {
    "EudraCT Number:": "2020-001937-11",
    "Sponsor Protocol Number:": "132333",
    "Sponsor Name:": "University College London",
    "Full Title:": "A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised p...",
    "Start Date:": "2020-04-30",
    "Medical condition:": "Respiratory illness caused by Covid-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001937-11",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001904-41",
    "Sponsor Protocol Number:": "GETAFIX-2020",
    "Sponsor Name:": "NHS Greater Glasgow and Clyde",
    "Full Title:": "Glasgow Early Treatment Arm FavIpiravir\uf063 : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients",
    "Start Date:": "2020-05-20",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001904-41"
  },
  {
    "EudraCT Number:": "2020-002120-37",
    "Sponsor Protocol Number:": "RESP301-002",
    "Sponsor Name:": "Thirty Respiratory Limited",
    "Full Title:": "An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C...",
    "Start Date:": "2020-06-16",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19) ",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10061986, Term: SARS, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002120-37"
  },
  {
    "EudraCT Number:": "2020-005395-35",
    "Sponsor Protocol Number:": "GatesMRI-COD-01-T01-01",
    "Sponsor Name:": "Bill & Melinda Gates Medical Research Institute",
    "Full Title:": "A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto\u00ae) for high risk people with mild COVID-19 ",
    "Start Date:": "2020-12-16",
    "Medical condition:": "Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks. "
  },
  {
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005395-35",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001072-15",
    "Sponsor Protocol Number:": "COV001",
    "Sponsor Name:": "University of Oxford",
    "Full Title:": "A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers",
    "Start Date:": "2020-03-26",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001072-15"
  },
  {
    "EudraCT Number:": "2020-004123-16",
    "Sponsor Protocol Number:": "2019nCoV-302",
    "Sponsor Name:": "Novavax, Inc.",
    "Full Title:": "A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1\u2122 ...",
    "Start Date:": "2020-09-23",
    "Medical condition:": "Prevention of COVID-19 caused by SARS-CoV-2",
    "Disease 1:": "Version: 23.1, SOC Term: 100000004865, Classification Code: 10084465, Term: COVID-19 vaccination, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16"
  },
  {
    "EudraCT Number:": "2020-001502-38",
    "Sponsor Protocol Number:": "VP-C21-006",
    "Sponsor Name:": "Vicore Pharma AB",
    "Full Title:": "A randomised, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation ",
    "Start Date:": "2020-05-06",
    "Medical condition:": "Covid-19 infection",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001502-38"
  },
  {
    "EudraCT Number:": "2020-001209-22",
    "Sponsor Protocol Number:": "PRINCIPLE",
    "Sponsor Name:": "University of Oxford / Clinical Trials and Research Governance ",
    "Full Title:": "Platform Randomised trial of INterventions against COVID-19 In older peoPLE",
    "Start Date:": "2020-03-26",
    "Medical condition:": "Suspected COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001209-22"
  },
  {
    "EudraCT Number:": "2020-001640-26",
    "Sponsor Protocol Number:": "132151",
    "Sponsor Name:": "University College London",
    "Full Title:": "A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial  ",
    "Start Date:": "2020-04-17",
    "Medical condition:": "Acute respiratory distress syndrome (ARDS) caused by COVID-19 ",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001640-26",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001886-35",
    "Sponsor Protocol Number:": "RHMCRI0399",
    "Sponsor Name:": "University Hospital Southampton NHS Foundation Trust",
    "Full Title:": "A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults",
    "Start Date:": "2020-05-15",
    "Medical condition:": "COVID-19 infection in patients requiring endotrachael intubation",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001886-35"
  },
  {
    "EudraCT Number:": "2020-002476-13",
    "Sponsor Protocol Number:": "20HH5958",
    "Sponsor Name:": "Imperial College London",
    "Full Title:": "A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. ",
    "Start Date:": "2020-07-24",
    "Medical condition:": "Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ...",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004857, Classification Code: 10023417, Term: Kidney dysfunction, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002476-13",
    "Disease 2:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10047463, Term: Viral infection NOS, Level: LLT",
    "Disease 3:": "Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10063321, Term: Interleukin level, Level: PT",
    "Disease 4:": "Version: 20.1, SOC Term: 10041244 - Social circumstances, Classification Code: 10079637, Term: Dependence on oxygen therapy, Level: PT"
  },
  {
    "EudraCT Number:": "2020-004144-28",
    "Sponsor Protocol Number:": "CCTU0307",
    "Sponsor Name:": "Cambridge university Hosptials NHS Foundation Trust and University of Cambridge",
    "Full Title:": "PROphylaxis for paTiEnts at risk of COVID-19 infecTion",
    "Start Date:": "2020-10-23",
    "Medical condition:": "",
    "Population Age:": "",
    "Gender:": "",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004144-28",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-004994-27",
    "Sponsor Protocol Number:": "2020SW03",
    "Sponsor Name:": "Ashford and St Peter's Hospitals NHS Foundation Trust",
    "Full Title:": "Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection",
    "Start Date:": "2020-12-16",
    "Medical condition:": "COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004994-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001805-21",
    "Sponsor Protocol Number:": "RA486120",
    "Sponsor Name:": "University Hospital Coventry & Warwickshire",
    "Full Title:": "Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 ",
    "Start Date:": "2020-05-15",
    "Medical condition:": "Sars-Cov-2",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001805-21",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001228-32",
    "Sponsor Protocol Number:": "COV002",
    "Sponsor Name:": "CTRG",
    "Full Title:": "A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19",
    "Start Date:": "2020-05-04",
    "Medical condition:": "SARS-CoV-2",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001228-32"
  },
  {
    "EudraCT Number:": "2020-001449-38",
    "Sponsor Protocol Number:": "CW002",
    "Sponsor Name:": "Chelsea and Westminster Hospital NHS Foundation Trust",
    "Full Title:": "A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe ",
    "Start Date:": "2020-04-29",
    "Medical condition:": "COVID-19 Infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38"
  },
  {
    "EudraCT Number:": "2020-002567-57",
    "Sponsor Protocol Number:": "1.0",
    "Sponsor Name:": "University of Oxford / Clinical Trials and Research Governance",
    "Full Title:": "To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support",
    "Start Date:": "2020-11-23",
    "Medical condition:": "Covid-19",
    "Disease 1:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002567-57"
  },
  {
    "EudraCT Number:": "2020-002668-29",
    "Sponsor Protocol Number:": "132796",
    "Sponsor Name:": "University College London",
    "Full Title:": "A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)  ",
    "Start Date:": "2020-06-25",
    "Medical condition:": "COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001996-33",
    "Sponsor Protocol Number:": "CD12_COVID-19",
    "Sponsor Name:": "CytoDyn, Inc.",
    "Full Title:": "A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO...",
    "Start Date:": "2020-08-26",
    "Medical condition:": "Coronavirus Disease 2019 (COVID-19)",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001996-33"
  },
  {
    "EudraCT Number:": "2020-002106-68",
    "Sponsor Protocol Number:": "CTU/2020/354",
    "Sponsor Name:": "University College London Comprehensive Clinical Trial Unit",
    "Full Title:": "Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19",
    "Start Date:": "2020-07-16",
    "Medical condition:": "SARS-CoV-2 (Corona virus) infection",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68"
  },
  {
    "EudraCT Number:": "2020-001643-13",
    "Sponsor Protocol Number:": "01.01.20",
    "Sponsor Name:": "University of Dundee",
    "Full Title:": "A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 ",
    "Start Date:": "2020-05-15",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001643-13"
  },
  {
    "EudraCT Number:": "2020-002230-32",
    "Sponsor Protocol Number:": "",
    "Sponsor Name:": "University of Edinburgh",
    "Full Title:": "Rapid Experimental Medicine for COVID-19 ",
    "Start Date:": "2020-06-23",
    "Medical condition:": "COVID-19",
    "Population Age:": "Under 18, Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001636-95",
    "Sponsor Protocol Number:": "282110",
    "Sponsor Name:": "University of Manchester",
    "Full Title:": "Subcutaneous and Intravenous anakinra in COVID-19 Infection -  Feasibility & Pharmacokinetics/ Pharmacodynamics study",
    "Start Date:": "2020-05-20",
    "Medical condition:": "Suspected or confirmed SARS-CoV-2 infection (confirmed by RNA-PCR)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95"
  },
  {
    "EudraCT Number:": "2020-002229-27",
    "Sponsor Protocol Number:": "TACTIC-E",
    "Sponsor Name:": "Cambridge University Hospitals NHS Foundation Trust",
    "Full Title:": "mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 \u2013 Experimental drugs and mechanisms  ",
    "Start Date:": "2020-06-09",
    "Medical condition:": "SARS-Cov-2",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002229-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001023-14",
    "Sponsor Protocol Number:": "SG016",
    "Sponsor Name:": "Synairgen Research Limited",
    "Full Title:": "A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN\u03b2-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...",
    "Start Date:": "2020-03-17",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14"
  },
  {
    "EudraCT Number:": "2020-004719-28",
    "Sponsor Protocol Number:": "D8850C00003",
    "Sponsor Name:": "AstraZeneca AB",
    "Full Title:": "A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...",
    "Start Date:": "2020-11-20",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004719-28"
  },
  {
    "EudraCT Number:": "2020-001786-36",
    "Sponsor Protocol Number:": "ILIAD-7-UK-Cohort",
    "Sponsor Name:": "RevImmune SAS France",
    "Full Title:": "Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection \u201cILIAD 7 trial\u201d",
    "Start Date:": "2020-05-06",
    "Medical condition:": "Lymphopenia and T cell exhaustion in  COVID-19 patients",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001786-36",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001354-22",
    "Sponsor Protocol Number:": "TACTIC-R",
    "Sponsor Name:": "Cambridge University Hospitals NHS Foundation Trust",
    "Full Title:": "Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)",
    "Start Date:": "2020-05-06",
    "Medical condition:": "COVID-19-related complications",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001354-22",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001473-79",
    "Sponsor Protocol Number:": "ESR-20-20653",
    "Sponsor Name:": "Saint Luke\u2019s Hospital of Kansas City, Kansas City, Missouri, USA",
    "Full Title:": "An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19",
    "Start Date:": "2020-05-07",
    "Medical condition:": "Respiratory Failure in patients with COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001473-79",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001860-27",
    "Sponsor Protocol Number:": "UoL001542",
    "Sponsor Name:": "University of Liverpool",
    "Full Title:": "AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment",
    "Start Date:": "2020-05-12",
    "Medical condition:": "Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001860-27"
  },
  {
    "EudraCT Number:": "2020-001684-89",
    "Sponsor Protocol Number:": "RG_20-030",
    "Sponsor Name:": "University of Birmingham",
    "Full Title:": "CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.",
    "Start Date:": "2020-05-05",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 20.1, SOC Term: 100000004855, Classification Code: 10047468, Term: Viral lower respiratory tract infections, Level: HLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89"
  },
  {
    "EudraCT Number:": "2020-001203-16",
    "Sponsor Protocol Number:": "LIBERATE",
    "Sponsor Name:": "Guy's and St Thomas' NHS Foundation Trust",
    "Full Title:": "Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial",
    "Start Date:": "2020-05-06",
    "Medical condition:": "COVID-19\u037e respiratory failure\u037e hypoxaemia.",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001203-16",
    "Disease 2:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT",
    "Disease 3:": "Version: 20.0, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10021141, Term: Hypoxaemia, Level: LLT"
  },
  {
    "EudraCT Number:": "2020-001113-21",
    "Sponsor Protocol Number:": "NDPHRECOVERY",
    "Sponsor Name:": "University of Oxford",
    "Full Title:": "Randomised Evaluation of COVID-19 Therapy (RECOVERY)",
    "Start Date:": "2020-03-17",
    "Medical condition:": "COVID-19 (infection with SARS-CoV-2 virus)",
    "Disease 1:": "Version: 21.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035737, Term: Pneumonia viral, Level: PT",
    "Population Age:": "Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21",
    "Disease 2:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061982, Term: Severe acute respiratory syndrome, Level: PT"
  },
  {
    "EudraCT Number:": "2020-002952-18",
    "Sponsor Protocol Number:": "Protocol",
    "Sponsor Name:": "Ashford and St Peter's Hospitals NHS Foundation Trust",
    "Full Title:": "Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19)",
    "Start Date:": "2020-07-21",
    "Medical condition:": "Confirmed Covid-19 infection by RT-PCR",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002952-18",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-000483-27",
    "Sponsor Protocol Number:": "CCT38473",
    "Sponsor Name:": "St.  Joseph\u2019s  Healthcare,  McMaster  University",
    "Full Title:": "Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis in ICU",
    "Start Date:": "2020-11-19",
    "Medical condition:": "critical illness requiring mechanical ventilation",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000483-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001441-39",
    "Sponsor Protocol Number:": "VIR20001",
    "Sponsor Name:": "University of Oxford",
    "Full Title:": "Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)",
    "Start Date:": "2020-05-12",
    "Medical condition:": "COVID-19, acute respiratory illness",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001441-39"
  },
  {
    "EudraCT Number:": "2020-002632-75",
    "Sponsor Protocol Number:": "CLI-050000-04",
    "Sponsor Name:": "CHIESI FARMACEUTICI S.p.A",
    "Full Title:": "Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf\u00ae) in hospitalized patients with SARS-COV-19 acute respiratory distr...",
    "Start Date:": "2020-07-08",
    "Medical condition:": "patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002632-75",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001396-33",
    "Sponsor Protocol Number:": "EPA-COV-001",
    "Sponsor Name:": "SLA Pharma (UK) Ltd",
    "Full Title:": "A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2",
    "Start Date:": "2020-11-13",
    "Medical condition:": "SARS-CoV-2",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084272, Term: SARS-CoV-2 infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001396-33"
  },
  {
    "EudraCT Number:": "2020-002494-10",
    "Sponsor Protocol Number:": "",
    "Sponsor Name:": "Queen Mary University of London",
    "Full Title:": "Personalised Electronic Record Supported OptimisatioN when ALone  for Patients with Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic ",
    "Start Date:": "2020-07-17",
    "Medical condition:": "Hypertension",
    "Disease 1:": "Version: 21.1, SOC Term: 100000004866, Classification Code: 10081425, Term: Arterial hypertension, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002494-10"
  },
  {
    "EudraCT Number:": "2020-002503-19",
    "Sponsor Protocol Number:": "62586",
    "Sponsor Name:": "UMC Utrecht",
    "Full Title:": "BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial ",
    "Start Date:": "2020-07-08",
    "Medical condition:": "SARS-CoV-2 infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004848, Classification Code: 10047490, Term: Virus identification and serology, Level: HLT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Ongoing) GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19"
  },
  {
    "EudraCT Number:": "2020-002211-21",
    "Sponsor Protocol Number:": "SGS.1656.201",
    "Sponsor Name:": "St George Street Capital Ltd",
    "Full Title:": "A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA...",
    "Start Date:": "2020-07-31",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) CZ(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002211-21"
  },
  {
    "EudraCT Number:": "2020-001736-95",
    "Sponsor Protocol Number:": "ACCORD-2-001,Sub002,003,006",
    "Sponsor Name:": "University Hospital Southampton NHS Foundation Trust",
    "Full Title:": "ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients ",
    "Start Date:": "2020-04-28",
    "Medical condition:": "COVID 19 ",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95"
  },
  {
    "EudraCT Number:": "2020-003486-19",
    "Sponsor Protocol Number:": "1.002.20",
    "Sponsor Name:": "University of Dundee",
    "Full Title:": "A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con...",
    "Start Date:": "2020-10-08",
    "Medical condition:": "Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection",
    "Disease 1:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10066724, Term: Acute pneumonia, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003486-19",
    "Disease 2:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT",
    "Disease 3:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084380, Term: COVID-19 pneumonia, Level: PT",
    "Disease 4:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001052, Term: Acute respiratory distress syndrome, Level: PT"
  },
  {
    "EudraCT Number:": "2020-001803-17",
    "Sponsor Protocol Number:": "GS-US-540-5823",
    "Sponsor Name:": "Gilead Sciences Inc.",
    "Full Title:": "A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734\u2122) in Participants from Birth to < 18 Years of Age with COVID-19",
    "Start Date:": "2020-07-14",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Newborns, Infants and toddlers, Children, Adolescents, Under 18",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17"
  },
  {
    "EudraCT Number:": "2020-003125-39",
    "Sponsor Protocol Number:": "TRI-08892",
    "Sponsor Name:": "CYTE Global",
    "Full Title:": "Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...",
    "Start Date:": "2020-10-30",
    "Medical condition:": "Low Molecular Weight Heparin (LMWH) thromboprophylaxis in patients with COVID-19 ",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) DE(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003125-39",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-003643-29",
    "Sponsor Protocol Number:": "VAC31518COV3009",
    "Sponsor Name:": "Janssen Vaccines & Prevention B.V.  ",
    "Full Title:": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older  E...",
    "Start Date:": "2020-11-10",
    "Medical condition:": "Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)",
    "Disease 1:": "Version: 23.1, SOC Term: 100000004865, Classification Code: 10084465, Term: COVID-19 vaccination, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) DE(Ongoing) ES(Temporarily Halted) BE(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003643-29"
  },
  {
    "EudraCT Number:": "2020-001807-18",
    "Sponsor Protocol Number:": "TD-0903-0188",
    "Sponsor Name:": "Theravance Biopharma Ireland Limited ",
    "Full Title:": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with...",
    "Start Date:": "2020-05-18",
    "Medical condition:": "Acute lung injury associated with COVID-19",
    "Disease 1:": "Version: 20.1, SOC Term: 100000004855, Classification Code: 10047468, Term: Viral lower respiratory tract infections, Level: HLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FI(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001807-18"
  },
  {
    "EudraCT Number:": "2020-003368-24",
    "Sponsor Protocol Number:": "MK-4482-002",
    "Sponsor Name:": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",
    "Full Title:": "A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19",
    "Start Date:": "2020-10-05",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) DE(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24"
  },
  {
    "EudraCT Number:": "2020-002542-16",
    "Sponsor Protocol Number:": "INSIGHT013",
    "Sponsor Name:": "Office of Sponsored Projects, Regents of the University of Minnesota",
    "Full Title:": "An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the...",
    "Start Date:": "2020-09-30",
    "Medical condition:": "COVID-19 (SARS-CoV-2) infection",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) GR(Ongoing) DK(Ongoing) DE(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002542-16"
  },
  {
    "EudraCT Number:": "2020-001497-30",
    "Sponsor Protocol Number:": "ALXN1210-COV-305",
    "Sponsor Name:": "Alexion Pharmaceuticals, Inc.",
    "Full Title:": "COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-1...",
    "Start Date:": "2020-05-07",
    "Medical condition:": "COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome",
    "Disease 1:": "Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061229, Term: Lung infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) ES(Temporarily Halted) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30"
  },
  {
    "EudraCT Number:": "2020-001689-12",
    "Sponsor Protocol Number:": "MHIPS-2020-001",
    "Sponsor Name:": "MONTREAL HEART INSTITUTE",
    "Full Title:": "COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)",
    "Start Date:": "2020-04-11",
    "Medical condition:": "Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "ES(Ongoing) GB(GB - no longer in EU/EEA) FR(Prematurely Ended) GR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-003367-26",
    "Sponsor Protocol Number:": "MK4482-001",
    "Sponsor Name:": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",
    "Full Title:": "A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19",
    "Start Date:": "2020-10-05",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) SE(Ongoing) PL(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003367-26"
  },
  {
    "EudraCT Number:": "2020-001172-15",
    "Sponsor Protocol Number:": "APN01-01-COVID19",
    "Sponsor Name:": "APEIRON Biologics AG",
    "Full Title:": "Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19",
    "Start Date:": "2020-04-08",
    "Medical condition:": "Severe COVID-19 POSITIVE hospitalized male or female, between 18 and \u2264 80 years of age",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) DK(Completed) AT(Completed) GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001662-11",
    "Sponsor Protocol Number:": "CINC424J12301",
    "Sponsor Name:": "Novartis Pharma AG",
    "Full Title:": "Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)",
    "Start Date:": "2020-05-05",
    "Medical condition:": "COVID-19 associated cytokine storm",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) GB(GB - no longer in EU/EEA) FR(Completed) ES(Ongoing) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001662-11",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-003510-12",
    "Sponsor Protocol Number:": "GS-US-540-9012",
    "Sponsor Name:": "Gilead Sciences, Inc",
    "Full Title:": "A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734\u2122) Treatment of COVID-19 in an Outpatient Setting",
    "Start Date:": "2020-10-02",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Completed) GB(GB - no longer in EU/EEA) PT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003510-12"
  },
  {
    "EudraCT Number:": "2020-001052-18",
    "Sponsor Protocol Number:": "010",
    "Sponsor Name:": "Regents of the University of Minnesota",
    "Full Title:": "A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...",
    "Start Date:": "2020-03-25",
    "Medical condition:": "Influenza COVID-19",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10022005, Term: Influenza viral infections, Level: HLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Completed) GB(Completed) DE(Completed) GR(Completed) ES(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001052-18"
  },
  {
    "EudraCT Number:": "2020-001270-29",
    "Sponsor Protocol Number:": "EFC16858",
    "Sponsor Name:": "sanofi-aventis recherche & d\u00e9veloppement",
    "Full Title:": "An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19",
    "Start Date:": "2020-04-08",
    "Medical condition:": "Coronavirus infection",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Prematurely Ended) CZ(Prematurely Ended) DE(Prematurely Ended) GB(Prematurely Ended) FR(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29"
  },
  {
    "EudraCT Number:": "2020-003278-37",
    "Sponsor Protocol Number:": "INSIGHT-014-ACTIV-3",
    "Sponsor Name:": "Regents of the University of Minesota",
    "Full Title:": "A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 ",
    "Start Date:": "2020-09-04",
    "Medical condition:": "Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.",
    "Disease 1:": "Version: 23.1, SOC Term: 10042613 - Surgical and medical procedures, Classification Code: 10084460, Term: COVID-19 treatment, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Restarted) GB(GB - no longer in EU/EEA) SE(Ongoing) GR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003278-37",
    "Disease 2:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT"
  },
  {
    "EudraCT Number:": "2020-004356-16",
    "Sponsor Protocol Number:": "D8850C00002",
    "Sponsor Name:": "AstraZeneca AB",
    "Full Title:": "A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...",
    "Start Date:": "2020-11-18",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) BE(Ongoing) FR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004356-16"
  },
  {
    "EudraCT Number:": "2020-004743-83",
    "Sponsor Protocol Number:": "SG018",
    "Sponsor Name:": "Synairgen Research Limited",
    "Full Title:": "A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19",
    "Start Date:": "2020-11-09",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) BE(Ongoing) PT(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83"
  },
  {
    "EudraCT Number:": "2020-001517-21",
    "Sponsor Protocol Number:": "I4V-MC-KHAA",
    "Sponsor Name:": "Eli Lilly and Company",
    "Full Title:": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib\u00a0in Patients with COVID-19 Infection",
    "Start Date:": "2020-06-30",
    "Medical condition:": "COVID-19 infection",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) DE(Ongoing) ES(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001517-21"
  },
  {
    "EudraCT Number:": "2020-001154-22",
    "Sponsor Protocol Number:": "WA42380",
    "Sponsor Name:": "F. Hoffmann-La Roche Ltd",
    "Full Title:": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.",
    "Start Date:": "2020-04-06",
    "Medical condition:": "Severe COVID-19 pneumonia",
    "Disease 1:": "Version: 21.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035737, Term: Pneumonia viral, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Completed) DE(Completed) FR(Completed) NL(Completed) GB(GB - no longer in EU/EEA) IT(Ongoing) ES(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001154-22"
  },
  {
    "EudraCT Number:": "2020-002979-35",
    "Sponsor Protocol Number:": "209348",
    "Sponsor Name:": "GlaxoSmithKline Research & Development Limited",
    "Full Title:": "A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chron...",
    "Start Date:": "2020-12-22",
    "Medical condition:": "Chronic Hepatitis B",
    "Disease 1:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10008910, Term: Chronic hepatitis B, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) PL(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002979-35"
  },
  {
    "EudraCT Number:": "2020-001498-63",
    "Sponsor Protocol Number:": "BIO101-CL05",
    "Sponsor Name:": "Biophytis S.A.",
    "Full Title:": "Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...",
    "Start Date:": "2020-07-22",
    "Medical condition:": "Confirmed infection with SARS-CoV-2 (COVID-19)",
    "Disease 1:": "Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10047465, Term: Viral infections NEC, Level: HLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "FR(Ongoing) BE(Ongoing) GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001498-63",
    "Disease 2:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT"
  },
  {
    "EudraCT Number:": "2020-001411-25",
    "Sponsor Protocol Number:": "XPORT-COV-1001",
    "Sponsor Name:": "Karyopharm Therapeutics Inc.",
    "Full Title:": "A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection",
    "Start Date:": "2020-05-18",
    "Medical condition:": "Severe COVID-19 Infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) FR(Completed) AT(Completed) GB(GB - no longer in EU/EEA) ES(Temporarily Halted) IT(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25"
  },
  {
    "EudraCT Number:": "2020-000842-32",
    "Sponsor Protocol Number:": "GS-US-540-5774",
    "Sponsor Name:": "Gilead Sciences, Inc.",
    "Full Title:": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment",
    "Start Date:": "2020-03-18",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Ongoing) ES(Completed) FR(Completed) IT(Completed) NL(Completed) GB(Completed) SE(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000842-32"
  },
  {
    "EudraCT Number:": "2018-002069-21",
    "Sponsor Protocol Number:": "D5180C00013",
    "Sponsor Name:": "AstraZeneca AB",
    "Full Title:": "A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C...",
    "Start Date:": "2018-10-23",
    "Medical condition:": "Severe Asthma",
    "Disease 1:": "Version: 20.0, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10003553, Term: Asthma, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DK(Completed) GB(GB - no longer in EU/EEA) DE(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002069-21"
  },
  {
    "EudraCT Number:": "2020-000841-15",
    "Sponsor Protocol Number:": "GS-US-540-5773",
    "Sponsor Name:": "Gilead Sciences, Inc.",
    "Full Title:": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants with Severe COVID-19",
    "Start Date:": "2020-03-18",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19)",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) ES(Completed) FR(Completed) IT(Completed) NL(Completed) GB(Completed) SE(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000841-15"
  },
  {
    "EudraCT Number:": "2020-001759-42",
    "Sponsor Protocol Number:": "214094",
    "Sponsor Name:": "GlaxoSmithKline Research & Development Limited",
    "Full Title:": "A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",
    "Start Date:": "2020-05-20",
    "Medical condition:": "Severe pulmonary COVID-19 related disease",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) NL(Ongoing) ES(Ongoing) BE(Ongoing) DE(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001759-42"
  },
  {
    "EudraCT Number:": "2020-001673-75",
    "Sponsor Protocol Number:": "ABX464-401",
    "Sponsor Name:": "ABIVAX",
    "Full Title:": "A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu...",
    "Start Date:": "2020-05-06",
    "Medical condition:": "COVID-19 infection (infection with SARS-CoV-2 virus)",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "FR(Prematurely Ended) DE(Completed) GB(GB - no longer in EU/EEA) ES(Ongoing) BE(Prematurely Ended) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2018-003898-94",
    "Sponsor Protocol Number:": "BN40955",
    "Sponsor Name:": "F.Hoffmann La-Roche Ltd",
    "Full Title:": "AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON\u2019S DISEASE ",
    "Start Date:": "2019-03-07",
    "Medical condition:": "Huntington's disease (HD)",
    "Disease 1:": "Version: 20.0, SOC Term: 10010331 - Congenital, familial and genetic disorders, Classification Code: 10070668, Term: Huntington's disease, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ES(Temporarily Halted) NL(Ongoing) AT(Temporarily Halted) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003898-94"
  },
  {
    "EudraCT Number:": "2015-002340-14",
    "Sponsor Protocol Number:": "REMAP-CAP",
    "Sponsor Name:": "University Medical Center Utrecht ",
    "Full Title:": "Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)",
    "Start Date:": "2015-09-16",
    "Medical condition:": "Severe Community Acquired Pneumonia",
    "Disease 1:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Ongoing) IE(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) HU(Ongoing) BE(Ongoing) DE(Ongoing) HR(Ongoing) ES(Ongoing) FR(Ongoing) FI(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14",
    "Disease 2:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",
    "COVID-19": ""
  },
  {
    "EudraCT Number:": "2020-001370-30",
    "Sponsor Protocol Number:": "CACZ885D2310",
    "Sponsor Name:": "Novartis Pharma AG",
    "Full Title:": "Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CA...",
    "Start Date:": "2020-04-29",
    "Medical condition:": "COVID-19-induced pneumonia (CAN-COVID)",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) GB(GB - no longer in EU/EEA) FR(Completed) ES(Ongoing) HU(Completed) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30"
  },
  {
    "EudraCT Number:": "2019-002621-30",
    "Sponsor Protocol Number:": "M19-063",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemi...",
    "Start Date:": "2020-06-10",
    "Medical condition:": "Acute Myeloid Leukemia (AML)",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) CZ(Ongoing) ES(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002621-30",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2018-000930-37",
    "Sponsor Protocol Number:": "M15-722",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",
    "Start Date:": "2018-12-21",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.1, SOC Term: 100000004856, Classification Code: 10045365, Term: Ulcerative colitis, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Ongoing) DE(Ongoing) GB(GB - no longer in EU/EEA) FR(Ongoing) ES(Ongoing) HU(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000930-37"
  },
  {
    "EudraCT Number:": "2017-001365-24",
    "Sponsor Protocol Number:": "WN39658",
    "Sponsor Name:": "Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en Espa\u00f1a y act\u00faa como representante de F.Hoffmann-La Roche LTD",
    "Full Title:": "A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER\u2019S DISEASE",
    "Start Date:": "2018-06-05",
    "Medical condition:": "Alzheimer\u2019s Disease (AD)",
    "Disease 1:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10001897, Term: Alzheimer's disease (incl subtypes), Level: HLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "ES(Ongoing) GB(GB - no longer in EU/EEA) DK(Ongoing) BE(Ongoing) PT(Ongoing) PL(Ongoing) NL(Ongoing) SE(Ongoing) FI(Ongoing) HR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001365-24",
    "Disease 2:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10074616, Term: Prodromal Alzheimer's disease, Level: PT"
  },
  {
    "EudraCT Number:": "2019-000954-67",
    "Sponsor Protocol Number:": "ATB200-07",
    "Sponsor Name:": "Amicus Therapeutics, Inc.",
    "Full Title:": "A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease",
    "Start Date:": "2020-04-08",
    "Medical condition:": "Adult Subjects With Late Onset Pompe Disease (LOPD)",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004850, Classification Code: 10075702, Term: Pompe's disease late onset, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ES(Ongoing) DE(Ongoing) DK(Ongoing) FR(Ongoing) BE(Ongoing) GR(Ongoing) SI(Ongoing) AT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000954-67"
  },
  {
    "EudraCT Number:": "2015-004726-34",
    "Sponsor Protocol Number:": "SHP620-302",
    "Sponsor Name:": "Shire ViroPharma Incorporated",
    "Full Title:": "A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...",
    "Start Date:": "2017-09-01",
    "Medical condition:": "Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10021819, Term: Infection in marrow transplant recipients, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "HU(Ongoing) DE(Ongoing) GB(GB - no longer in EU/EEA) ES(Ongoing) BE(Ongoing) CZ(Ongoing) PL(Ongoing) FR(Ongoing) HR(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004726-34"
  },
  {
    "EudraCT Number:": "2016-002154-20",
    "Sponsor Protocol Number:": "CLCZ696G2301",
    "Sponsor Name:": "Novartis Pharma Services AG",
    "Full Title:": "A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk ...",
    "Start Date:": "2017-03-28",
    "Medical condition:": "Left ventricular dysfunction following an acute myocardial infarction.",
    "Disease 1:": "Version: 20.0, SOC Term: 10007541 - Cardiac disorders, Classification Code: 10000891, Term: Acute myocardial infarction, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) PT(Completed) CZ(Completed) GB(GB - no longer in EU/EEA) GR(Completed) AT(Completed) SK(Completed) NL(Completed) ES(Completed) HU(Completed) BE(Completed) DK(Completed) SE(Completed) FI(Completed) BG(Completed) HR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002154-20"
  },
  {
    "EudraCT Number:": "2016-004676-22",
    "Sponsor Protocol Number:": "M16-066",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who ...",
    "Start Date:": "2019-01-14",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "BE(Ongoing) SK(Ongoing) AT(Ongoing) ES(Ongoing) SE(Ongoing) NL(Ongoing) DK(Ongoing) GR(Ongoing) PL(Ongoing) DE(Ongoing) LT(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) SI(Ongoing) BG(Ongoing) HR(Ongoing) FR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004676-22"
  },
  {
    "EudraCT Number:": "2016-000674-38",
    "Sponsor Protocol Number:": "M14-533",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)",
    "Start Date:": "2016-09-20",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "SK(Ongoing) NL(Ongoing) CZ(Ongoing) AT(Ongoing) FI(Ongoing) PL(Ongoing) SE(Completed) GB(GB - no longer in EU/EEA) DE(Ongoing) LV(Ongoing) GR(Ongoing) EE(Ongoing) IE(Ongoing) HU(Ongoing) PT(Ongoing) LT(Ongoing) BE(Ongoing) NO(Ongoing) ES(Ongoing) HR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000674-38"
  },
  {
    "EudraCT Number:": "2016-003191-50",
    "Sponsor Protocol Number:": "M16-000",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease",
    "Start Date:": "2017-08-23",
    "Medical condition:": "Crohn's disease",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004856, Classification Code: 10013099, Term: Disease Crohns, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "SK(Ongoing) DK(Ongoing) DE(Ongoing) PT(Ongoing) CZ(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) IE(Ongoing) BG(Ongoing) AT(Ongoing) PL(Ongoing) NL(Ongoing) EE(Ongoing) SE(Ongoing) ES(Ongoing) GR(Ongoing) NO(Ongoing) LT(Ongoing) BE(Ongoing) HR(Ongoing) FR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003191-50"
  }
]